Growth Hormone Peptides Canada: A Complete Research Guide

Introduction: why growth hormone peptides Canada researchers study matter#

The interest in growth hormone peptides Canada researchers and international groups share has grown steadily over the past two decades. These are not new molecules. Many of the key compounds in this family, sermorelin, the GHRPs, CJC-1295, were characterised between the 1970s and the mid-2000s. What has changed is the accessibility of synthesis-grade versions, the growth of a serious preclinical literature around them, and the realisation that the somatotropic axis offers useful experimental handles for questions about body composition, ageing, and endocrine signalling that were previously hard to approach without recombinant human GH.

This guide covers the category in full. It is a research resource, not a protocol. Every compound discussed here is either a research chemical in Canada or, in the case of tesamorelin, a compound whose approved indication is narrow and whose broader research applications are studied under research-use conditions. Nothing in this guide constitutes advice for human therapeutic use, and Canadian researchers should be clear about that framing before they engage with this material.

The category groups together molecules that share a functional goal, stimulating the body's own pituitary to release growth hormone, but that achieve that goal through different structural strategies and at different points in the somatotropic axis. Understanding where each molecule sits in that axis, and what it is actually doing to the receptor it binds, is the precondition for understanding the literature on any individual compound. For a faster receptor-lane matrix before reading the full pillar, use the growth-hormone secretagogue comparison guide. For the adjacent myostatin/activin brake-release lane that is often misfiled beside GH peptides, use the Follistatin-344 Canada guide instead of forcing it into a secretagogue framework.

Two receptor families dominate the map. GHRH analogues bind the growth hormone releasing hormone receptor on pituitary somatotroph cells and mimic or extend the endogenous hypothalamic signal. GHRP class peptides, and the non-peptide MK-677, bind the ghrelin receptor on the same cells and provide a second, complementary GH-releasing signal. The distinction matters at every level: mechanism, pharmacokinetics, selectivity, side-effect profile, stacking rationale, and sourcing complexity.

One more framing point is worth establishing early. Growth hormone peptides are not recombinant human GH. Recombinant somatropin delivers the hormone itself, directly, bypassing the pituitary and the endogenous feedback systems. GH secretagogues work by asking the pituitary to do what it already knows how to do, which means the resulting GH signal is still pulsatile, still subject to somatostatin braking, and still shaped by the individual's endogenous biology. That is a meaningful difference for any research design.

---

The GH axis: how endogenous growth hormone release works#

Before examining individual molecules, it is worth mapping the signalling pathway they act on. Every compound in this family intersects the same axis. Understanding that axis is the foundation for understanding why half-life, pulse shape, and timing all matter so much in growth hormone peptide research.

Rendering diagram...

The hypothalamus releases GHRH in pulses that recur roughly every two to three hours in humans, with the largest and most frequent pulses occurring during slow-wave sleep in the first few hours of the night. Between those pulses, somatostatin from the hypothalamus and periventricular nucleus actively suppresses GH release from the pituitary, functioning as a tonic brake on somatotroph activity.

The stomach and gut contribute a third input via ghrelin, a 28 amino acid acylated peptide released primarily in response to fasting. Ghrelin binds the growth hormone secretagogue receptor (GHSR-1a) on pituitary somatotrophs and on hypothalamic neurons. Its effect is to amplify GH release, both by direct action at the pituitary and by stimulating hypothalamic GHRH release while simultaneously suppressing somatostatin.

When somatotrophs receive an integrated signal from all three inputs, they release GH in a pulse that passes into circulation and acts on peripheral tissues. In the liver, GH stimulates the production of insulin-like growth factor 1 (IGF-1), which mediates most of the downstream biological effects associated with GH signalling: protein synthesis, lipolysis, and cell proliferation. IGF-1 feeds back negatively to the hypothalamus and pituitary, suppressing GHRH release, increasing somatostatin tone, and directly dampening somatotroph responsiveness. This negative feedback loop is the reason GH pulses are self-limiting.

GHRH analogues drive the first arrow in that diagram. GHRPs and MK-677 drive the ghrelin arrow. Neither family bypasses the somatostatin brake entirely, though GHRPs appear to partially attenuate it, which is part of the mechanistic rationale for combining the two families in a stack. Understanding the feedback loop is also essential for understanding the risks of prolonged high-frequency stimulation, which the later section on axis suppression addresses.

---

The two families: GHRH analogues vs GH secretagogues#

The single most useful mental model for this category is the two-receptor framework. GHRH analogues bind the GHRH receptor (GHRHR), a Gs protein-coupled receptor that signals through cyclic AMP and ultimately leads to GH gene transcription and exocytosis. GHRPs and MK-677 bind GHSR-1a, a Gq protein-coupled receptor that signals through phospholipase C, protein kinase C, and intracellular calcium. Because these two pathways converge on GH release through distinct intracellular mechanisms, they can be combined without simple competitive inhibition of one by the other.

That mechanistic independence is the formal reason the GHRH analogue plus GHRP stack is supra-additive in published research rather than merely additive. Each family is working through its own pathway, and the pituitary somatotroph integrates both signals. Adding a GHRH analogue on top of a GHRP produces a larger pulse than doubling the dose of either one, because doubling the dose of a single compound eventually saturates its own receptor class while doing nothing for the other pathway.

This also clarifies why selecting the wrong GHRP is a research design issue rather than merely a preference issue. GHRP-2 and GHRP-6 stimulate GHSR-1a effectively but also produce measurable cortisol and prolactin release. Ipamorelin does not. If the research question is specifically about GH pulse amplitude without hormonal confounders, the GHRP choice matters enormously, and ipamorelin is the right choice for reasons described below.

---

GHRH analogues in depth#

Sermorelin: the historical anchor#

Sermorelin was the first synthetic GHRH analogue developed for clinical investigation and remains a widely studied reference compound. Its structure corresponds to the first 29 amino acids of native human GHRH(1-44), which was identified and sequenced in the early 1980s following the discovery by Guillemin's group that a pancreatic tumour was producing a hypothalamic releasing factor. The truncated 29 amino acid version retains the N-terminal domain responsible for receptor binding and biological activity while discarding the less functionally critical C-terminal tail.

The plasma half-life of sermorelin is approximately 10 to 20 minutes after subcutaneous administration. This reflects its susceptibility to cleavage by dipeptidyl peptidase IV (DPP-IV) at the His-Ala site near the N-terminus and by other circulating peptidases. The brief half-life is both a limitation and a feature, depending on the research question. For studies examining pulse-by-pulse GH dynamics or for short-duration stimulation tests, the rapid clearance is useful. For studies requiring sustained GHRH signalling, sermorelin is usually replaced by a longer-acting analogue.

Sermorelin received US FDA approval in 1997 under the brand name Geref for the evaluation of GH secretion in children with possible GH deficiency, and for the long-term treatment of GH deficiency in children with idiopathic GH deficiency. This makes it one of the few GHRH analogues with a well-documented regulatory and clinical history, and its characterised pharmacokinetic profile in both paediatric and adult populations is part of why it persists as a useful reference compound.

CJC-1295 without DAC: the pulsatile analogue#

CJC-1295 without DAC, also described in the literature as modified GRF(1-29) or Mod-GRF(1-29), is a synthetic GHRH analogue that retains sermorelin's short-acting, pulsatile character but incorporates amino acid substitutions that increase binding affinity and resistance to enzymatic degradation. Four substitutions at positions 2, 8, 15, and 27 of the native sequence replace amino acids that are particularly vulnerable to DPP-IV and other peptidases without disrupting the bioactive conformation of the N-terminal helix.

The plasma half-life remains roughly 30 minutes, meaningfully longer than sermorelin but still short enough to produce a discrete, time-limited GH pulse. For researchers who want a GHRH signal that fires on a predictable schedule, retains pulsatility, and then clears, CJC-1295 without DAC is the most commonly used tool in the class. Its pulse shape closely mirrors the endogenous GHRH-driven pulse, which matters for research designs that want to preserve physiological GH rhythmicity.

The compound is often paired with ipamorelin as a pre-blended preparation, which is discussed in the stacking section below. When used alone, research protocols in the published literature have typically administered it one to three times daily, timing around periods of low somatostatin tone, which in practice means away from carbohydrate and fat-containing meals.

CJC-1295 with DAC: the albumin-binding variant#

CJC-1295 with DAC is the same GHRH peptide sequence conjugated to a drug affinity complex (DAC), specifically a maleimidopropionic acid-lysine linker attached to the epsilon amine of a lysine residue incorporated into the C-terminal extension of the peptide. The maleimide group of the linker reacts with a free thiol on circulating serum albumin to form a stable covalent bond, effectively hitching the peptide to the body's most abundant plasma protein.

Albumin has a half-life of approximately 19 to 21 days in humans. By binding to it covalently, CJC-1295 with DAC gains a dramatically extended functional half-life: published human pharmacokinetic data shows sustained GH elevation and elevated IGF-1 for six to eight days after a single dose, with some studies reporting measurable IGF-1 elevation at day 14. This transforms the compound from a pulsatile GHRH signal into a sustained, tonic GHRH background.

The implications for research design are significant. CJC-1295 with DAC does not produce discrete GH pulses in the way that sermorelin or no-DAC CJC-1295 does. Instead, it raises the basal level of GHRH signalling continuously. GH release still occurs in pulses, because the somatostatin brake remains intact and pituitary somatotrophs still respond to somatostatin-driven inhibition, but the amplitude and frequency of those pulses are elevated compared to baseline throughout the dosing interval.

This is a fundamentally different experimental tool from the short-acting GHRH analogues. Researchers studying pulse dynamics, acute GH responses, or short time-course interventions should use sermorelin or no-DAC CJC-1295. Researchers studying sustained GHRH receptor activation, prolonged IGF-1 elevation, or the downstream consequences of weeks of augmented GH secretion are more likely to reach for CJC-1295 with DAC. The two compounds are not interchangeable, which is why the confusion between them in the grey market is a genuine research-validity problem.

For a detailed treatment of the with-DAC versus without-DAC comparison, the Northern Compound post at /blog/growth-hormone-peptides-guide works through the pharmacokinetics, research applications, and sourcing considerations in depth.

Tesamorelin: the clinical benchmark#

Tesamorelin occupies a distinct position in the GHRH analogue class because it is the only member with a significant published clinical evidence base and an approved therapeutic indication. Structurally, it is a full-length GHRH(1-44) analogue, unlike the truncated sermorelin, with a trans-3-hexenoic acid group attached to the alpha amino group of the N-terminal tyrosine. That modification protects the peptide against DPP-IV cleavage at the His-Ala bond and against other N-terminal peptidases without disrupting receptor binding.

The resulting pharmacokinetics are those of a short-to-intermediate-acting GHRH analogue. The plasma half-life is approximately 26 to 38 minutes after subcutaneous administration, peak plasma concentrations are reached within the first 15 to 30 minutes, and the downstream IGF-1 response begins to rise measurably within the first few days of repeated dosing.

The clinical dataset for tesamorelin centres on HIV-associated lipodystrophy, a condition characterised by central visceral fat accumulation in patients receiving antiretroviral therapy. The pivotal trials, including the work of Falutz and colleagues published in the New England Journal of Medicine in 2010, found that daily subcutaneous tesamorelin significantly reduced visceral adipose tissue and elevated GH and IGF-1 compared to placebo in this population. The compound was subsequently approved by the US FDA under the brand name Egrifta for this specific indication.

For Canadian researchers, tesamorelin is notable for reasons beyond its approval. It is the GHRH analogue with the most thoroughly characterised human dose-response relationship, the most complete safety dataset, and the most rigorous peer-reviewed evidence linking GHRH receptor stimulation to downstream metabolic outcomes. That evidence base makes it a common reference compound in preclinical and observational research investigating the relationship between GH axis signalling and body composition, even when the specific context is not HIV-related lipodystrophy.

The tesamorelin section of this guide examines its structure, pharmacokinetics, clinical trial data, and research applications.

---

GH secretagogues: ipamorelin and the GHRP family#

The GHRP family shares the GHSR-1a target but varies significantly in selectivity, potency, and off-target effects. Choosing between them in a research context is not arbitrary. Each compound has a distinct profile, and that profile shapes the conclusions that can be drawn from any experiment that uses it.

Ipamorelin: the selective GHRP#

Ipamorelin is a synthetic pentapeptide, five amino acids in sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2), developed by Novo Nordisk in the late 1990s. It was designed specifically for selectivity at GHSR-1a, and the published evidence confirms that selectivity: at doses that produce robust GH release in research models, ipamorelin does not meaningfully stimulate ACTH and cortisol, prolactin, thyroid-stimulating hormone, or luteinising hormone.

That selectivity distinguishes ipamorelin from every other GHRP studied in the literature. GHRP-2, GHRP-6, and hexarelin all produce measurable cortisol or prolactin elevation at GH-stimulating doses, because GHSR-1a signalling in those compounds cross-activates HPA axis pathways to varying degrees. Ipamorelin, through what appears to be a combination of receptor binding geometry and downstream signalling pathway selectivity, avoids those cross-activations.

For a researcher who wants a clean GHRP signal without hormonal confounders, ipamorelin is the tool of choice. For a researcher who specifically wants to probe the ghrelin pathway and its interactions with appetite or cortisol regulation, ipamorelin's selectivity is actually a limitation, and GHRP-6 or GHRP-2 might be more informative tools.

The plasma half-life of ipamorelin is approximately 2 hours, somewhat longer than most GHRPs, which influences dosing cadence in multi-dose protocols. Its appetite-stimulating effect is present but generally mild compared to GHRP-6, consistent with the broader selectivity profile. The comparison with sermorelin is covered in the research-design sections below.

Hexarelin: potency at the cost of selectivity#

Hexarelin is a synthetic hexapeptide (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) and one of the most potent GHSR-1a agonists by molecular weight studied in the published literature. It produces substantially larger GH pulses than ipamorelin at equivalent molar doses, but it is less selective. Measurable cortisol and prolactin elevation occur at GH-stimulating concentrations, and the compound also produces tachyphylaxis, a progressive desensitisation of the GH response with repeated dosing, more readily than ipamorelin.

Hexarelin has drawn research attention beyond the GH axis for a separate reason: GHSR-1a is expressed in cardiac tissue, and hexarelin has demonstrated cardioprotective effects in ischaemia-reperfusion animal models that appear at least partly independent of GH release. Whether those effects involve GHSR-1a signalling in the myocardium directly, or are mediated via GH and IGF-1 systemically, remains an active research question. Hexarelin is the compound most often used to probe that question. The dedicated Hexarelin Canada guide now covers that molecule-specific evidence map, including why potency, cardiovascular-model relevance, ACTH/cortisol/prolactin spillover, and lot-specific COA checks need to be evaluated together.

GHRP-2 and GHRP-6: the earlier generation#

GHRP-2 is a second-generation hexapeptide ghrelin receptor agonist (D-Ala-D-betaNal-Ala-Trp-D-Phe-Lys-NH2) developed as an improvement on the first-generation GHRP-6. It produces reliable and substantial GH release but with documented effects on cortisol and prolactin. Its potency per milligram is higher than GHRP-6 and its appetite-stimulating effect is generally milder, which has made it the preferred reference GHRP for endocrinology experiments where the investigator wants a robust GH pulse as a control condition and can tolerate mild cortisol and prolactin elevation as a known confounder.

GHRP-6 is the archetypal first-generation GHRP, a hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that defined the class. Its single most discussed characteristic in the research literature is its pronounced appetite-stimulating effect, which reflects the full ghrelin-mimetic profile of the compound. In ghrelin biology research, where the appetite dimension of GHSR-1a signalling is specifically the thing under investigation, GHRP-6 is a more useful tool than the cleaner, more selective options. For researchers who want GH release without appetite confounds, it is not the first choice.

---

MK-677 (ibutamoren): the oral, non-peptide exception#

MK-677 (ibutamoren) sits in the same functional family as the GHRPs but is structurally and pharmacologically distinct in ways that matter for research design. It is not a peptide. It is a spiroindoline small molecule developed by Merck in the 1990s as part of a programme to find orally bioavailable ghrelin receptor agonists. The compound binds GHSR-1a with high affinity and selectivity, producing GH and IGF-1 elevation in a manner mechanistically similar to ipamorelin, but through a small-molecule scaffold rather than a peptide backbone.

The key pharmacological differences are its oral bioavailability and its half-life. MK-677 is active when taken orally, which sets it apart from every injectable GHRP in the class. Its terminal half-life in human studies is approximately 24 hours after oral dosing, which means once-daily dosing produces a roughly continuous elevation of GH and IGF-1 throughout the day rather than the discrete pulses produced by short-acting injectables.

That sustained GH profile is the primary reason MK-677 has been studied in contexts where a pulsatile experimental design is impractical or where sustained IGF-1 elevation is the target outcome. Published human studies have examined MK-677 in sarcopenia models in older adults (Nuttall et al., 1997 and Chapman et al., 1996 are early examples), in sleep architecture studies where the effect on slow-wave sleep duration was the primary endpoint, and in investigational programmes for growth hormone deficiency.

The tonic, continuous GH elevation produced by MK-677 also raises the axis suppression considerations discussed in the feedback section below. The compound does not preserve the pulsatile architecture of endogenous GH secretion in the way that short-acting GHRPs do, and long-duration protocols raise questions about sustained IGF-1 elevation and the downstream effects of reduced GH pulse amplitude.

For a Canadian research programme, MK-677 also represents a logistically distinct category: it is supplied as an oral preparation rather than a lyophilised injectable peptide, does not require reconstitution, and its storage requirements differ from the rest of the class.

---

The CJC-1295 and ipamorelin stack: synergy rationale and research timing#

The canonical research pairing in the growth hormone peptide category is a GHRH analogue combined with a GHRP, and the most commonly cited version of that pairing is CJC-1295 without DAC combined with ipamorelin. The rationale is mechanistic, not conventional.

As established earlier, the GHRH receptor (GHRHR) and the ghrelin receptor (GHSR-1a) signal through distinct intracellular pathways: Gs and cAMP for GHRHR, Gq and phospholipase C for GHSR-1a. When both receptors are activated simultaneously on the same somatotroph, their downstream signals converge on the exocytosis machinery independently, producing a GH pulse that is larger than the sum of either signal alone. Published animal studies, including the work of Bowers and colleagues, demonstrate this supra-additivity clearly in GH pulse measurements. Human pharmacodynamic studies using the CJC-1295 and ipamorelin combination show GH area-under-curve values approximately three to five times larger than ipamorelin alone and substantially larger than GHRH alone at equivalent doses.

There is also a second mechanism contributing to the synergy. GHRPs appear to partially attenuate the somatostatin brake that normally caps GHRH-driven GH release. Somatostatin, released by the hypothalamus and periventricular nucleus, suppresses GH release by acting on somatostatin receptors on somatotrophs. GHRPs reduce somatostatin secretion from hypothalamic neurons and may also directly oppose somatostatin signalling at the pituitary level. When a GHRH analogue and a GHRP are administered together, the GHRH drives the somatotroph to release GH while the GHRP partially lifts the somatostatin brake, resulting in a larger net pulse.

From a research timing perspective, the optimal window for administering this combination in published protocols is during periods of low somatostatin tone. In practice this means:

• Away from carbohydrate and fat-rich meals (a post-prandial insulin spike raises somatostatin tone and blunts GH release)
• During or shortly before the sleep window (slow-wave sleep is naturally associated with low somatostatin and large GH pulses)
• At a consistent interval so that results can be compared across measurements

For protocols comparing the no-DAC and with-DAC variants in a stack context, a key consideration is that CJC-1295 with DAC circulates for days and therefore the GHRP still needs to be dosed multiple times per day for the two compounds to be simultaneously active at the pituitary. This logistical asymmetry is one reason most published stack protocols use the no-DAC form for pulse-synchronised designs. For researchers interested in the specific question of tonic GHRH signalling combined with acute GHRP pulses, the with-DAC form provides a different experimental handle.

For a broader discussion of research stack combinations involving growth hormone peptides and adjacent compound classes, see /blog/best-peptides-weight-loss-canada, which covers the weight management context where GH secretagogue stacks are often investigated alongside GLP-1 research.

---

IGF-1 as a downstream research marker#

Researchers studying the somatotropic axis almost universally use IGF-1 rather than GH itself as their primary biomarker. Understanding why, and understanding how to interpret IGF-1 measurements in the context of growth hormone peptide protocols, is essential background.

Growth hormone itself is released in discrete pulses that last 10 to 30 minutes and then clear rapidly from circulation. Measuring GH directly requires frequent sampling (every 20 minutes or more for several hours) to capture the pulsatile architecture, and single GH measurements are essentially meaningless because they reflect only whether the sample happened to be drawn during a pulse or in the interpulse trough. Practically all population-level research on GH status uses IGF-1 instead.

IGF-1 is produced primarily in the liver in response to GH stimulation, but its production integrates GH exposure over a period of hours to days rather than reflecting moment-to-moment GH concentration. The result is a far more stable biomarker: IGF-1 concentration changes slowly, is not acutely affected by a single high-GH measurement, and provides a reasonable rolling average of GH axis activity over the preceding few days.

Published reference ranges for serum IGF-1 are age and sex adjusted, because IGF-1 declines significantly with age. In young adult males (20 to 30 years), typical ranges are approximately 115 to 307 ng/mL; in the 40 to 50 year range, they drop to approximately 86 to 255 ng/mL; and in adults over 60, they may be 55 to 175 ng/mL or lower. These ranges vary between laboratory assays, which is why within-study comparisons are generally more informative than cross-study comparisons that use different reference panels.

In growth hormone peptide research, IGF-1 is used to assess whether a GHRH analogue or GHRP protocol is producing measurable downstream axis activation. A protocol that does not elevate IGF-1 compared to baseline is likely not producing a GH signal large enough to drive hepatic IGF-1 production. A protocol that markedly elevates IGF-1 into the upper quartile or above the reference range may be delivering a signal larger than what the research question requires and raises the axis suppression questions addressed below.

IGF-1 LR3, the long-acting IGF-1 analogue, is a separate research tool that acts directly at the IGF-1 receptor rather than upstream at the GH axis. It is occasionally used alongside GH secretagogues in multi-arm studies examining GH-versus-IGF-1 pathway contributions, but the two tools are generally kept separate to maintain clean mechanistic interpretation.

---

GH axis feedback and suppression risks#

Any research programme using growth hormone peptides needs to account for the negative feedback systems that govern the somatotropic axis, because those systems do not switch off simply because external GH-releasing signals are present.

The two primary feedback mechanisms are IGF-1-mediated suppression and somatostatin-mediated suppression. IGF-1 produced in the liver in response to elevated GH feeds back to the hypothalamus to reduce GHRH secretion, feeds back to the pituitary to reduce somatotroph sensitivity and GH exocytosis, and stimulates hypothalamic somatostatin release. This means that as GH rises and drives IGF-1 up, the system self-corrects: endogenous GHRH production falls, somatostatin tone rises, and pituitary responsiveness to both endogenous GHRH and exogenous GHRH analogues decreases.

In acute experiments, this feedback is relatively slow to engage. A single dose of a GHRH analogue produces a GH pulse that resolves over 30 to 90 minutes, and the IGF-1 response is too slow to provide meaningful within-hours feedback. In longer-duration protocols, particularly those using CJC-1295 with DAC (which sustains GHRH signalling for days) or MK-677 (which elevates GH and IGF-1 continuously), the feedback systems have time to establish a new equilibrium.

Published data from longer human studies with tesamorelin and MK-677 show that sustained GH and IGF-1 elevation does not produce a progressive runaway increase; the feedback systems set a new ceiling. However, the relevant research question is whether that sustained signalling also attenuates endogenous GH pulse amplitude, either because somatotrophs become less sensitive after prolonged activation or because elevated somatostatin tone (driven by elevated IGF-1) clamps pulsatile release.

There is evidence for both effects in the literature. Long-duration MK-677 studies show that while IGF-1 remains elevated, the amplitude of individual GH pulses may be reduced relative to the protocol baseline, consistent with increased somatostatin tone. This has implications for research designs that measure GH pulse architecture as an endpoint: sustained tonic stimulation protocols may actually reduce the measurable pulse size even as they raise the IGF-1 baseline.

For researchers, the practical implication is that protocol design should match the compound's mechanism to the measurement objective. Pulsatile short-acting peptides (sermorelin, no-DAC CJC-1295, ipamorelin) preserve pulse architecture and are appropriate for pulse-dynamics studies. Sustained-action compounds (CJC-1295 with DAC, MK-677) raise IGF-1 more consistently across the measurement window but should not be used when pulse amplitude is the outcome of interest.

---

Recombinant HGH vs GH secretagogues: a comparison for researchers#

Growth hormone peptides are sometimes described informally as alternatives to recombinant human GH (rHGH, also called somatropin), but the two categories differ in mechanistically important ways that make them appropriate for different research questions.

Recombinant somatropin is the human GH protein itself, produced via recombinant DNA technology in bacteria or mammalian cell expression systems. When administered subcutaneously or intramuscularly, it bypasses the pituitary entirely: the GH is delivered directly into circulation, where it binds GH receptors in the liver and peripheral tissues. The pituitary plays no role in this process. Endogenous feedback systems respond to the exogenously delivered GH, but the pituitary is not the site of action.

GH secretagogues, by contrast, act entirely upstream of the GH protein itself. They stimulate the pituitary to release GH, meaning the resulting GH signal is shaped by the pituitary's own response capacity, by the prevailing somatostatin tone, and by the endogenous feedback systems. The pituitary is not bypassed; it is recruited.

This distinction has several downstream implications. First, recombinant GH produces a pharmacokinetic profile determined by the formulation and injection route, not by the pituitary's release timing. Short-acting somatropin peaks and clears over a few hours; long-acting preparations circulate for days. GH secretagogues produce a GH signal whose shape reflects the pituitary's own release kinetics, which generally means a pulse of 30 to 90 minutes regardless of which upstream analogue drove it. Second, recombinant GH does not require a functional pituitary; GH secretagogues do. A research subject with pituitary failure will not respond to any GH secretagogue. Third, supraphysiological GH levels are more readily achieved with recombinant GH, which can simply be dosed to deliver whatever circulating concentration is desired. GH secretagogues are capped by the somatostatin brake.

For Canadian research programmes, the regulatory distinction matters as well. Recombinant somatropin is a Schedule F prescription drug in Canada, regulated under the Food and Drugs Act. GH secretagogue peptides are not approved therapeutics for general use, and are supplied as research chemicals. The different regulatory status shapes what is practically accessible in a non-clinical research context and why the growth hormone peptide class rather than rHGH is the more common starting point for academic and independent research.

---

Reconstitution, handling, and storage for this compound class#

Growth hormone peptides are supplied as lyophilised (freeze-dried) powder in sealed glass vials, typically in fills of 1, 2, 5, or 10 milligrams. Proper reconstitution is a prerequisite for research validity, and the mechanics differ slightly between the short-acting injectables and the DAC-modified version.

For sermorelin, CJC-1295 without DAC, ipamorelin, and the GHRP family, the standard reconstitution protocol involves adding bacteriostatic water (0.9% benzyl alcohol in sterile water for injection) slowly down the side of the vial rather than directly onto the peptide cake. The peptide dissolves by diffusion rather than by mechanical disruption. Swirling gently is acceptable; shaking is not. Reconstituted solutions should be stored refrigerated at 2 to 8°C and used within 14 to 30 days, depending on the specific peptide and storage conditions. Repeated freeze-thaw cycles after reconstitution degrade stability and should be avoided.

For CJC-1295 with DAC, the albumin-binding maleimide linker adds some sensitivity to the reconstitution conditions. Aggressive handling or exposure to free thiol groups in reconstitution buffers before injection can partially inactivate the DAC functionality. Using standard bacteriostatic water without thiol-containing additives and handling gently preserves the albumin-binding capacity.

Tesamorelin is often supplied with a specific recommended diluent volume and concentration designed to match the clinical formulation. Deviating from that volume for convenience creates inconsistencies in research records and should be avoided.

Lyophilised powder stored at -20°C or below in a sealed vial with desiccant is stable for extended periods, often several years, provided it has not been exposed to moisture or temperature cycling. Once reconstituted, the stability window shortens substantially, which is why research groups running infrequent protocols typically reconstitute only what they need for a defined window rather than reconstituting an entire vial at the start of a project.

For step-by-step reconstitution instructions with troubleshooting detail, Northern Compound's dedicated guide at /blog/how-to-reconstitute-peptides covers the full workflow. For certificate of analysis documentation and what to look for, /blog/research-peptides-canada-buyers-guide explains what a credible batch-level COA contains and how to verify it against the product in hand.

---

Canadian regulatory context and sourcing considerations#

The regulatory environment for growth hormone peptides in Canada involves the Food and Drugs Act, the Food and Drug Regulations, and Health Canada's policies on the importation and sale of research chemicals. Researchers working in this space should be familiar with the relevant framework.

Sermorelin, CJC-1295 (both forms), ipamorelin, hexarelin, GHRP-2, and GHRP-6 are not approved therapeutic drugs in Canada for general human use. They are available as research chemicals for laboratory and preclinical investigation, supplied with documentation indicating they are for research purposes only. Tesamorelin, under the Egrifta brand, has an approved therapeutic indication in some jurisdictions (primarily HIV-associated lipodystrophy), but its supply outside that specific approved context is subject to the same research-chemical classification as the rest of the class.

MK-677 occupies a somewhat different regulatory position because it is a small molecule rather than a peptide, and small molecules have historically been evaluated against Schedule I and Schedule IV of the Controlled Drugs and Substances Act as well as the Food and Drugs Act. Researchers should verify the current regulatory status of MK-677 under Canadian federal law before incorporating it into any programme.

For domestic sourcing, the key quality signals in the growth hormone peptide category are:

Batch-specific certificates of analysis: Every batch of every compound should carry a third-party COA showing HPLC purity (at minimum, ideally ESI-MS or LC-MS as well) with the specific batch number that matches the number on the vial. A COA with no batch number, a COA for a different compound, or a COA shared across multiple batches of the same compound are all disqualifying. The COA documentation is the one signal that cannot be faked at the vial level if the supplier commits to batch-level matching.

Domestic shipping and cold chain: Growth hormone peptides are temperature-sensitive in reconstituted form. Suppliers who ship with ice packs or controlled-temperature packaging and who ship from within Canada avoid the cross-border complications and thermal exposure risks that affect international supply. Domestic supply also ensures the researcher is not navigating Canada Border Services Agency clearance for each order.

Transparent company information: A domestic Canadian address, contact information, and visible business registration are basic due-diligence markers. Anonymous suppliers with no traceable company structure are a risk category regardless of what their marketing materials claim.

Price as a noisy signal: The grey market for growth hormone peptides includes both legitimate research suppliers and sources selling underfilled or impure product at headline-grabbing low prices. The functional consequence of a CJC-1295 preparation that is 60% pure rather than 98% pure is an effective dose roughly 40% lower than expected, plus whatever the contaminant is. Neither outcome is acceptable in serious research. Price alone does not predict quality, but price well below the domestic market average is a reliable flag for closer scrutiny.

Lynx Labs operates from Canada, publishes batch-specific third-party COAs for the full growth hormone peptide range, and stocks all major compounds discussed in this guide, including a pre-blended CJC-1295 and ipamorelin preparation that simplifies the stacking workflow for researchers who prefer a single vial. For a broader evaluation of the Canadian peptide supply landscape across all compound classes, Northern Compound's sourcing guide at /blog/research-peptides-canada-buyers-guide covers supplier evaluation criteria in depth.

---

Common research pitfalls in this compound class#

Seven recurring errors show up in the growth hormone peptide research literature and in discussions among Canadian research groups often enough to merit explicit attention.

The DAC vs no-DAC confusion: CJC-1295 with DAC and CJC-1295 without DAC share almost identical names, are often stocked side by side at the same supplier, and look identical as a lyophilised white powder. Their pharmacokinetics differ by roughly a factor of 300 in half-life. A protocol designed for no-DAC CJC-1295 (short-acting, dosed daily) run with the DAC version will produce a sustained GHRH signal that accumulates over days to weeks, not a series of discrete pulses. The reverse error produces a short, rapidly clearing signal instead of the sustained elevation expected. Neither error produces valid data for the intended research question. Read the molecular weight on the COA, which will differ between the two forms, and verify it matches the compound description.

Timing relative to meals: GH secretion is physiologically suppressed by post-prandial insulin and by free fatty acids in circulation, both of which raise somatostatin tone. Administering a GHRH analogue or GHRP in the one to two hours after a carbohydrate or fat-containing meal reliably blunts the GH response and produces an underestimated effect. Protocols that do not control for meal timing find variable GH responses that they then attribute to the peptide, when the variability is almost entirely from the feeding window. Fasted administration, or timing at a consistent interval post-meal, is the minimum control needed for reproducible data.

Single IGF-1 measurements: IGF-1 varies with meals, sleep quality, acute stress, and day-to-day biological variation enough that a single pre-post measurement cannot reliably attribute a change to a growth hormone peptide protocol. Research designs that use a single baseline measurement and a single post-protocol measurement typically produce inconclusive results with wide confidence intervals. Time-series designs, with three to five measurements taken at consistent conditions over the protocol period, produce far more interpretable data.

Ignoring tachyphylaxis in hexarelin protocols: Hexarelin is the most potent GHRP by weight, but repeated daily dosing produces progressive desensitisation of the GH response, likely through GHSR-1a internalisation or downstream receptor pathway desensitisation. Researchers who observe a strong first-dose response and then a declining response across a multi-week hexarelin protocol are encountering a known pharmacological phenomenon, not analytical error. Ipamorelin shows less tachyphylaxis over typical research intervals, which is another reason for its preference in longer-duration protocols.

Conflating the GH peptide class with recombinant HGH: Research conclusions about GH secretagogues are not transferable to recombinant somatropin and vice versa. Secretagogues act upstream; somatropin acts downstream. A finding that a GHRH analogue raises IGF-1 does not mean it produces the same downstream biology as direct GH administration, because the pulsatility, feedback loop engagement, and receptor kinetics differ substantially.

Freeze-thaw damage after reconstitution: Reconstituted growth hormone peptide solutions tolerate refrigeration at 2 to 8°C well, but tolerate freeze-thaw cycles poorly. A vial that has been frozen in solution, thawed, and frozen again is producing unreliable results even if the original lyophilised material was analytically clean. Label vials with reconstitution date and avoid freezing the solution once made.

Poor laboratory notebook documentation: The CJC-1295 DAC versus no-DAC confusion and the GHRP-2 versus GHRP-6 confusion are the most common documentation failures in this category, but the broader principle applies to every vial. Lyophilised white powders look identical. Recording the compound name, batch number, vial fill, reconstitution date, reconstitution volume, and resulting concentration directly on the label or tag attached to the vial is the cheapest quality control step available to any research group.

---